
Opinion|Videos|October 17, 2024
Impact of IPF on Quality of Life and Financial Considerations
Author(s)Toby Maher, MD, PhD
Key Takeaways
- IPF severely impacts quality of life, limiting daily activities due to progressive respiratory decline.
- Median survival for IPF patients is approximately 3 to 5 years post-diagnosis.
Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) severely affects patients’ quality of life and daily functioning, with a median survival that underscores the disease’s severity, while also highlighting the substantial financial burden and health care resource utilization associated with managing this condition.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How does IPF impact a patient’s quality of life and ability to perform activities of daily living? What is the median survival for patients with IPF?
- Can you describe the financial impact and health care resource utilization for patients with IPF?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
2
Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives
3
IgA Nephropathy, FSGS Care Needs Coordinators, Not Just New Drugs
4
Complicated UTI Care Strained by Unclear Goals, Access Gaps
5



